Organism: Homo sapiens
Gene: 39637_at
Selected probe(set): 224959_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array

Expression of 39637_at (224959_at) across 6674 perturbations tested by GENEVESTIGATOR:

Relative Expression (log2-ratio):-5.025343
Number of Samples:16 / 6

Experimental	ulcerative colitis study 5 (baseline; non-responder)
	Colonic mucosal biopsies derived from ulcerative colitis patients who are non-responders to infliximab treatment. Biopsies were taken within a week prior to the first intravenous infusion of infliximab; the response to infliximab was assessed 4 to 6 weeks after the first infliximab treatment. The response was defined as a complete mucosal healing with a decrease of at least 3 points on the histological score for Crohn's disease (CDc) and as a decrease to a Mayo endoscopic subscore of 0 or 1 with a decrease to grade 0 or 1 on the histological score for ulcerative colitis (UC). More strict response criteria were used for Crohn's ileitis (CDi). More baseline information about the patients are available in the publication.
Control	normal colon mucosa tissue
	Colonic mucosal biopsy from control subject obtained at the endoscopy for polyps screening.

Relative Expression (log2-ratio):-4.6626654
Number of Samples:3 / 7

Experimental	colorectal adenoma study 4 (large)
	Rectum biopsies of colorectal adenomas (size: 3cm - 4cm).
Control	adjacent colon mucosa tissue
	Biopsies of rectum mucosa from adjacent tumor tissue.

Relative Expression (log2-ratio):-4.14909
Number of Samples:4 / 2

Experimental	colorectal cancer study 33 (carcinoma; cecum)
	Primary tumor samples derived from the cecum of patients with carcinoma.
Control	normal cecum tissue
	Normal cecal tissue samples.

Relative Expression (log2-ratio):-4.1458044
Number of Samples:3 / 3

Experimental	colorectal cancer study 13 (tvvad)
	Colon biopsies derived from patients with low grade tubulovillous/villous adenoma.
Control	normal colon tissue
	Colon biopsies derived from healthy controls.

Relative Expression (log2-ratio):4.111787
Number of Samples:8 / 9

Experimental	hepatocyte (ESC)
	Hepatocyte-like cells differentiated from embryonic stem cells (ESC)
Control	Hep-G2
	Human primary cancer cell line derived from the liver of a patient with hepatocellular carcinoma. Synonyms:HEP-G2; Hep G2; HEP G2; HepG2; HEPG2 Cellosaurus code:

Relative Expression (log2-ratio):-4.1097393
Number of Samples:5 / 5

Experimental	colorectal adenoma study 7 (colonic mucosa)
	Colonic mucosa samples obtained by laser capture microdissection (LCM) from patients with colorectal adenoma.
Control	normal colon mucosa sample
	Histopathological normal colon mucosa sample obtained by laser capture microdissection (LCM) from the distant normal colon of patients with colorectal cancer.

Relative Expression (log2-ratio):-4.104724
Number of Samples:3 / 4

Experimental	colorectal adenoma study 1 (small)
	Ascending colon biopsies of colorectal adenomas (size: 1cm - 2cm).
Control	adjacent colon mucosa tissue
	Biopsies of ascending colon mucosa from adjacent tumor tissue.

Relative Expression (log2-ratio):4.08545
Number of Samples:3 / 3

Experimental	influenza virus study 9 (A/pH1N1)
	Human carcinoma cell line A549 infected with influenza A virus subtype [A/Singapore/478/2009 (pH1N1)]. Samples were taken 10 hours post-infection.
Control	influenza virus study 4 (A/H1N1)
	Human carcinoma cell line A549 infected with influenza A virus subtype A/WSN/33 (H1N1). Samples were taken 10 hours post-infection.

Relative Expression (log2-ratio):3.9851189
Number of Samples:2 / 3

Experimental	brefeldin A study 1 (0.5ug/ml; p53HCT116)
	Derived human colon carcinoma cell line p53HCT116 with knockout gene for p53 was treated with 0.5 ug/ml brefeldin-A for 24 hours in McCOYs 5A medium supplemented with 10% heat inactivated FBS. ATC code:---
Control	untreated p53HCT116 cell sample
	Derived human colon carcinoma cell line p53HCT116 with knockout gene for p53 was grown in McCOYs 5A medium supplemented with 10% heat inactivated FBS.

Relative Expression (log2-ratio):-3.979598
Number of Samples:8 / 6

Experimental	ulcerative colitis study 5 (baseline; responder)
	Colonic mucosal biopsies derived from ulcerative colitis patients who are responders to infliximab treatment. Biopsies were taken within a week prior to the first intravenous infusion of infliximab; the response to infliximab was assessed 4 to 6 weeks after the first infliximab treatment. The response was defined as a complete mucosal healing with a decrease of at least 3 points on the histological score for Crohn's disease (CDc) and as a decrease to a Mayo endoscopic subscore of 0 or 1 with a decrease to grade 0 or 1 on the histological score for ulcerative colitis (UC). More strict response criteria were used for Crohn's ileitis (CDi). More baseline information about the patients are available in the publication.
Control	normal colon mucosa tissue
	Colonic mucosal biopsy from control subject obtained at the endoscopy for polyps screening.